Abstract 1425P
Background
Timely diagnosis with complete molecular profiling is essential in advanced lung cancer. Although tissue sampling remains the gold standard, liquid biopsies provide an alternative option for timely molecular characterization, especially for epidermal growth factor receptor (EGFR) testing in lung cancer.
Methods
All patients referred at the Centre Hospitalier de l’Université de Montréal (CHUM) with a radiological suspicion of advanced lung cancer and no known prior tumour molecular testing were prospectively screened and consented. Plasma and tissue samples were retrieved for EGFR testing and mutations were analyzed using Cobas® cell-free DNA (cfDNA). The CLEAR study evaluated plasma and tissue EGFR testing and the clinical impact on the management of suspected lung cancer patients.
Results
Between November 2019 and January 2023, a total of 312 patients were initially screened for eligibility for inclusion in the study and 7 patients were excluded for history of treated lung cancer. Median age was 68 years, 55% were female, 17% were non-smokers, and 30% were active smokers. 83% had non-small cell lung cancer and 70% of patients had stage IV disease. 8% and 10% EGFR mutations were detected by cfDNA and tissue biopsy, respectively. EGFR exon 19 deletion was the most frequent mutation, detected in 59% of patients. Median time to EGFR result was 28 days and 3 days for tissue and plasma sampling, respectively. cfDNA was 100% specific and 72% sensitive for EGFR status. Positive predictive value was 100% and the negative predictive value was 95%. Osimertinib was initiated within a median of 12 days of cfDNA results and up to 21 days before tissue results. Cranial radiotherapy was avoided in 6 EGFR-positive patients with brain metastases.
Conclusions
Early detection of EGFR mutations by cfDNA reduces time to diagnosis and accelerates therapy initiation. Cobas® assay is specific, with high positive and negative predictive values. Decreased delays to access targeted therapy can decrease improper treatment choices and alleviate complications of untreated disease while awaiting molecular results from tissue biopsies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
Y. Kim, I. Syed, N. Devost, G. Kenth: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. D. Hui: Financial Interests, Personal, Full or part-time Employment: AstraZeneca. N. Blais: Financial Interests, Personal, Funding: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20